LENSAR (NASDAQ:LNSR – Free Report) had its price target upped by Lake Street Capital from $12.00 to $16.00 in a research note published on Friday,Benzinga reports. They currently have a buy rating on the stock.
LENSAR Stock Up 19.6 %
LNSR opened at $13.00 on Friday. LENSAR has a 52-week low of $2.67 and a 52-week high of $13.18. The company has a 50 day moving average of $9.58 and a two-hundred day moving average of $7.05. The company has a market cap of $151.00 million, a P/E ratio of -8.90 and a beta of 0.66.
LENSAR (NASDAQ:LNSR – Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($1.61) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.40). LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%. The firm had revenue of $16.73 million for the quarter, compared to analyst estimates of $14.95 million.
Institutional Inflows and Outflows
About LENSAR
LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.
Recommended Stories
- Five stocks we like better than LENSAR
- Health Care Stocks Explained: Why You Might Want to Invest
- MarketBeat Week in Review – 02/24 – 02/28
- What Are Some of the Best Large-Cap Stocks to Buy?
- 3 Companies Buying Back Stock – Why They’re Doubling Down
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
Receive News & Ratings for LENSAR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENSAR and related companies with MarketBeat.com's FREE daily email newsletter.